We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
- Authors
Reddy, Jay P.; Hernandez, Mike; Gunther, Jillian R.; Dabaja, Bouthaina S.; Martin, Geoffrey V.; Jiang, Wen; Akhtari, Mani; Allen, Pamela K.; Atkinson, Bradley J.; Smith, Grace L.; Pinnix, Chelsea C.; Milgrom, Sarah A.; Abou Yehia, Zeinab; Osborne, Eleanor M.; Oki, Yasuhiro; Lee, Hun; Hagemeister, Fredrick; Fanale, Michelle A.
- Abstract
Summary: To determine whether pre‐treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early‐stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut‐off point values to define progression. Two‐year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (<italic>P</italic> < 0·001). Similarly, 2‐year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (<italic>P</italic> = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (<italic>P</italic> = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (<italic>P</italic> < 0·001).
- Subjects
NEUTROPHILS; LYMPHOCYTES; BLOOD platelets; HODGKIN'S disease; DISEASE relapse
- Publication
British Journal of Haematology, 2018, Vol 180, Issue 4, p545
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.15054